entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 13:44:23 - browse：5265

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.

Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.

The “Roi” in Roivant stands for “return on investment” and with this deal, the biotech, founded by Republican presidential candidate Vivek Ramaswamy but now run by CEO Matt Gline, certainly delivered. Last December, it essentially acquired RVT-3101 from Pfizer for $45 million and a commitment to invest in the drug’s development. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Hearing on Medicare drug price negotiation gets unusually heated

WSS

Unique patient identifier: Experts argue the benefits, pitfalls

Thermo Fisher plant for manufacturing gene therapies to expand

Medical student insurance fails on mental health care coverage

Bernie brings in new pharma CEOs to talk drug prices

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Johnson & Johnson sued for allegedly overpaying for workers' drugs

knowledge

entertainment

explore

Affirmative action in medical school literally saved lives

EpiPen alternative approval delay highlights citizen petition issue

In Memoriam: Notable people who died in 2023

Drug for rare kidney disease narrowly misses mark in clinical trial

Anesthesiologist group: stop taking Ozempic before surgery

Thermo Fisher plant for manufacturing gene therapies to expand

What does generative AI mean for health care? We asked experts

Why Novartis is going to walk from its acquisition of MorphoSys

Medical records are filled with copy

Adopting new red light myopia treatments may be short

focus

Biotech stock slump in 2023: awaiting the turnaround

EpiPen alternative approval delay highlights citizen petition issue

Biotech stock slump in 2023: awaiting the turnaround

Lasker Awards 2023: Winners in biomedical research

Problems with a popular proposal to regulate AI in health care

CDC's new outbreak response network to include Northeastern

Wikipedia

knowledge

Wikipedia

knowledge